Anixa Biosciences Inc 10-Q

Item 5. Other Information. None. Item 6. Exhibits. 10.1 Amendment No. 1 to Exclusive License Agreement between The Cleveland Clinic Foundation and Anixa Biosciences, Inc. (Certain information has been redacted in the marked portions of the exhibit.) 31.1 Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated September 9, 2022. 31.2 Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated September 9, 2022. 32.1 Statement of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated September 9, 2022. 32.2 Statement of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated September 9, 2022. 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase 101.LAB Inline XBRL Taxonomy Extension Label Linkbase 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) 25 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized. ANIXA BIOSCIENCES, INC. By: /s/ Dr. Amit Kumar Dr. Amit Kumar Chairman and Chief Executive Officer September 9, 2022 (Principal Executive Officer) By: /s/ Michael J. Catelani Michael J. Catelani President, Chief Operating Officer and Chief Financial Officer (Principal Financial and September 9, 2022 Accounting Officer) 26